Genelux Co. (NASDAQ:GNLX – Get Free Report) major shareholder Aladar Szalay sold 48,683 shares of Genelux stock in a transaction on Tuesday, April 16th. The stock was sold at an average price of $3.53, for a total transaction of $171,850.99. Following the transaction, the insider now directly owns 1,322,862 shares of the company’s stock, valued at $4,669,702.86. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Large shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.
Genelux Price Performance
Shares of GNLX opened at $3.86 on Friday. Genelux Co. has a 12-month low of $3.42 and a 12-month high of $40.98. The firm has a fifty day moving average price of $6.25 and a 200-day moving average price of $11.64.
Institutional Trading of Genelux
Large investors have recently made changes to their positions in the stock. Vanguard Group Inc. boosted its stake in shares of Genelux by 1,660.1% during the third quarter. Vanguard Group Inc. now owns 980,993 shares of the company’s stock valued at $24,025,000 after purchasing an additional 925,258 shares during the period. AE Wealth Management LLC lifted its stake in Genelux by 1,370.0% in the third quarter. AE Wealth Management LLC now owns 194,875 shares of the company’s stock worth $4,772,000 after acquiring an additional 181,618 shares during the period. D.A. Davidson & CO. purchased a new stake in Genelux in the third quarter worth about $237,000. Advisor Resource Council purchased a new stake in Genelux in the fourth quarter worth about $233,000. Finally, Barclays PLC lifted its stake in Genelux by 516.4% in the third quarter. Barclays PLC now owns 3,384 shares of the company’s stock worth $83,000 after acquiring an additional 2,835 shares during the period. 37.33% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analysts Forecast Growth
Read Our Latest Analysis on GNLX
Genelux Company Profile
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer.
See Also
- Five stocks we like better than Genelux
- Investing in the High PE Growth Stocks
- Comprehensive PepsiCo Stock Analysis
- Low PE Growth Stocks: Unlocking Investment Opportunities
- CSX Co.: The Railroad Powering Ahead with an Earnings Beat
- Biggest Stock Losers – Today’s Biggest Percentage Decliners
- Bear Market Funds to Watch This Year
Receive News & Ratings for Genelux Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genelux and related companies with MarketBeat.com's FREE daily email newsletter.